Biological Therapies in Oncology: Balancing Efficacy and Safety in the Context of Latent Tuberculosis.
作者信息
Akl Maher Monir, Ahmed Amr
机构信息
Department of Chemistry, Faculty of Science, Mansoura University, 35516, Mansoura, Egypt.
The Public Health Department, Riyadh First Health Cluster, Ministry of Health, Saudia Arabia.
出版信息
Adv Pharm Bull. 2024 Dec 30;14(4):714-715. doi: 10.34172/apb.43269. Epub 2024 Oct 2.
Abstract
摘要
相似文献
1
Biological Therapies in Oncology: Balancing Efficacy and Safety in the Context of Latent Tuberculosis.肿瘤学中的生物疗法：在潜伏性结核病背景下平衡疗效与安全性
Adv Pharm Bull. 2024 Dec 30;14(4):714-715. doi: 10.34172/apb.43269. Epub 2024 Oct 2.
2
Screening for Latent Tuberculosis Infection in Patients who are Candidate for Biological Therapies in Spain? A Multidisciplinary Survey.西班牙生物治疗候选患者的潜伏性结核感染筛查？一项多学科调查。
Arch Bronconeumol (Engl Ed). 2018 Oct;54(10):510-517. doi: 10.1016/j.arbres.2018.04.004. Epub 2018 Jun 23.
3
A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab.一项关于接受司库奇尤单抗治疗的潜伏性结核银屑病患者结核状态和结核感染γ-干扰素释放试验（TB-IGRA）值变化的倾向评分匹配研究。
Dermatol Ther (Heidelb). 2023 Oct;13(10):2387-2401. doi: 10.1007/s13555-023-00998-w. Epub 2023 Aug 24.
4
[10 years of innovation in the treatment of latent tuberculosis infection: a comparison between standard and short course therapies in directly observed therapy].潜伏性结核感染治疗的十年创新：直接观察治疗中标准疗法与短程疗法的比较
Rev Esp Sanid Penit. 2011;13(1):3-14. doi: 10.4321/s1575-06202011000100002.
5
Latent tuberculosis infection screening prior to biological treatment in Tunisian patients.突尼斯患者生物治疗前的潜伏性结核感染筛查。
Therapie. 2017 Oct;72(5):573-578. doi: 10.1016/j.therap.2017.02.002. Epub 2017 Feb 24.
6
Evolving therapies for rifampicin-resistant tuberculosis: balancing efficacy and toxicity.耐利福平结核病的不断演进的治疗方法：平衡疗效与毒性
Lancet Respir Med. 2020 Apr;8(4):326-328. doi: 10.1016/S2213-2600(20)30038-2. Epub 2020 Mar 17.
7
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy.生物疗法治疗银屑病患者潜伏性结核病再激活的风险：来自意大利北部一家三级保健中心的回顾性队列研究。
Acta Derm Venereol. 2022 Nov 29;102:adv00821. doi: 10.2340/actadv.v102.1982.
8
The Relationship Between Work Engagement and Safety Behaviour of Oncology Nurses: A Latent Profile Analysis.肿瘤护理人员工作投入与安全行为的关系：潜在剖面分析
J Adv Nurs. 2025 Mar 5. doi: 10.1111/jan.16863.
9
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.在潜伏性结核感染的现实环境中，接受司库奇尤单抗治疗的银屑病患者未出现结核病再激活情况。
J Dermatolog Treat. 2022 Aug;33(5):2629-2633. doi: 10.1080/09546634.2022.2062280. Epub 2022 Apr 11.
10
Treatment of latent tuberculosis infection in patients receiving biologic agents.治疗接受生物制剂治疗的患者中的潜伏性结核感染。
J Infect Chemother. 2021 Feb;27(2):243-249. doi: 10.1016/j.jiac.2020.09.028. Epub 2020 Oct 6.
本文引用的文献
1
From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning.从免疫学到人工智能：机器学习在潜伏性结核感染诊断中的革命。
Mil Med Res. 2023 Nov 28;10(1):58. doi: 10.1186/s40779-023-00490-8.
2
Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review.癌症疫苗治疗学：局限性和有效性——文献综述。
Cells. 2023 Aug 28;12(17):2159. doi: 10.3390/cells12172159.
3
Updating the Definition of Cancer.更新癌症定义。
Mol Cancer Res. 2023 Nov 1;21(11):1142-1147. doi: 10.1158/1541-7786.MCR-23-0411.
4
Immunotherapies against HER2-Positive Breast Cancer.针对HER2阳性乳腺癌的免疫疗法。
Cancers (Basel). 2023 Feb 8;15(4):1069. doi: 10.3390/cancers15041069.
5
The Biological and Clinical Aspects of a Latent Tuberculosis Infection.潜伏性结核感染的生物学及临床特征
Trop Med Infect Dis. 2022 Mar 8;7(3):48. doi: 10.3390/tropicalmed7030048.
6
Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor.肿瘤坏死因子抑制剂导致潜伏性结核分枝杆菌病的再激活：IL-12 受体β2 链的关键作用。
Cell Mol Immunol. 2021 Jul;18(7):1644-1651. doi: 10.1038/s41423-021-00694-9. Epub 2021 May 21.
7
Monoclonal Antibodies in Cancer Therapy.癌症治疗中的单克隆抗体
Antibodies (Basel). 2020 Jul 20;9(3):34. doi: 10.3390/antib9030034.
8
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.癌症免疫疗法的历史与进展：了解肿瘤浸润免疫细胞的特征及其治疗意义。
Cell Mol Immunol. 2020 Aug;17(8):807-821. doi: 10.1038/s41423-020-0488-6. Epub 2020 Jul 1.
9
PD-1/PD-L1 pathway: current researches in cancer.PD-1/PD-L1 通路：癌症领域的当前研究
Am J Cancer Res. 2020 Mar 1;10(3):727-742. eCollection 2020.
10
Treatment of Latent Tuberculosis Infection-An Update.潜伏结核感染的治疗：最新进展。
Clin Chest Med. 2019 Dec;40(4):839-848. doi: 10.1016/j.ccm.2019.07.008.
Zotero 插件